Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a mixed outlook: while there are positive aspects such as strong software performance and a stable tax rate, challenges in China and revised growth forecasts temper enthusiasm. The Q&A reveals cautious optimism, especially with expected recovery in diagnostics and software, but management's unclear responses on AI and new product contributions suggest uncertainty. Overall, the sentiment is balanced, reflecting both potential and risks, leading to a neutral rating.
Key Financial Performance
Organic Growth 1% organic growth in Q3 2025, slightly offset by less favorable FX tailwinds due to currency changes. Signals software business grew 20% organically, driven by strong SaaS performance and conversion. Reproductive health business grew mid-single digits year-over-year, with newborn screening growing in the high single digits.
Adjusted Operating Margins 26.1% adjusted operating margins in Q3 2025, modestly above expectations but down 220 basis points year-over-year. Year-over-year decline due to tariffs, FX, and lower volume leverage, particularly in Diagnostics business in China. Partially offset by cost containment initiatives.
Adjusted Earnings Per Share (EPS) $1.18 adjusted EPS in Q3 2025, $0.05 above the midpoint of guidance. Increase attributed to better-than-expected operating margins and additional favorability below the line.
Free Cash Flow $120 million free cash flow in Q3 2025, representing approximately 90% of adjusted net income. Year-to-date free cash flow of $354 million, equating to 89% conversion of adjusted net income.
Share Repurchase $205 million spent on share repurchases in Q3 2025, buying back approximately 2.3 million shares. Total buyback activity since divestiture 2.5 years ago amounts to 12.5 million shares or 10% of total shares outstanding at the end of Q1 2023.
Revenue $699 million revenue in Q3 2025, resulting in 1% organic growth. Diagnostics segment grew 2% organically, while Life Sciences segment was flat. Geographically, low single-digit growth in the Americas, mid-single-digit growth in Europe, and mid-single-digit decline in Asia, with China declining in the low teens.
Diagnostics Business in China Diagnostics business in China declined in the mid-20s in Q3 2025 due to DRG-related declines in volume. Excluding China, the other 80% of the immunodiagnostics business grew in the high single digits, with mid-teens growth in the Americas.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Signals software business: Grew 20% organically in Q3, with stronger SaaS performance and conversion.
NeoLSD 7-plex kit: Received IVDR approval in Europe and awaiting FDA clearance. Expanded assay includes screening for MPS-II (Hunter's syndrome).
AI-based software offerings: Launched products like Signals One, Transcribe AI, Phenologic.AI, and Living Image Synergy AI. These solutions improve productivity and scientific advancements.
Geographic performance: Low single-digit growth in Americas, mid-single-digit growth in Europe, and mid-single-digit decline in Asia. China declined in low teens.
Strategic partnerships: Collaborations with Genomics England for newborn screening and Sanofi for type 1 diabetes assay development.
Adjusted operating margins: Achieved 26.1%, modestly above expectations.
Free cash flow: Generated $120 million in Q3, representing 90% of adjusted net income.
Share repurchase program: Repurchased $205 million worth of shares in Q3, with a new $1 billion authorization for future buybacks.
AI integration: Deployed Revvity AI for 11,000 employees, improving lead generation, software development timelines, and financial operations.
Sustainability efforts: Achieved 6% reduction in Scope 1 and 2 emissions and diverted 47% of waste from landfills in 2024.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Dynamic End Market Environment: The company is operating in a dynamic end market environment, which could pose challenges in maintaining stable demand and customer confidence.
Foreign Exchange (FX) Tailwinds: Less favorable FX tailwinds due to currency changes impacted organic growth slightly in the third quarter.
China Diagnostics Business: The diagnostics business in China faced a low teens organic decline, with immunodiagnostics declining over 20% due to DRG-related volume declines.
Tariffs and FX Impact on Margins: Adjusted operating margins were pressured year-over-year due to tariffs and FX, along with lower volume leverage.
Customer Spending Trends: Customer spending has not yet returned to historically normal levels, creating uncertainty in demand trends.
Regulatory Approvals: Some new products, such as the NeoLSD 7-plex kit, are awaiting regulatory approvals, which could delay market entry and revenue generation.
Economic Conditions in China: Economic conditions in China, including DRG-related declines, are negatively impacting the diagnostics business.
Interest Income Reduction: Lower interest earnings on cash balances due to increased share repurchase activity impacted net interest and other expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Revvity expects organic revenue growth of 2% to 4% for the full year 2025, with both Life Sciences and Diagnostics segments projected to grow in the low single digits. The company anticipates total revenue to be in the range of $2.83 billion to $2.88 billion.
Adjusted Operating Margins: The company expects adjusted operating margins to be in the range of 27.1% to 27.3% for the full year 2025, assuming the current tariff environment remains unchanged.
Adjusted Earnings Per Share (EPS): Revvity has raised its adjusted EPS guidance to a range of $4.90 to $5 for the full year 2025, reflecting a $0.05 increase from prior expectations.
2026 Organic Growth Outlook: For 2026, Revvity projects organic growth to remain in the 2% to 3% range, with potential for improvement if customer spending returns to historically normal levels. The company remains confident in achieving a 28% adjusted operating margin baseline for 2026 due to ongoing restructuring activities.
AI-Driven Product Development: Revvity is actively embedding AI capabilities into its product offerings, with a robust pipeline of AI-based solutions expected to come to market soon. These innovations aim to transform scientific paradigms and preclinical discovery.
Strategic Partnerships: The company is advancing key partnerships, including collaborations with Genomics England for newborn genetic screening and Sanofi for early screening of type 1 diabetes. These initiatives are expected to contribute meaningfully to the Diagnostics franchise upon regulatory approvals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Activity: In the third quarter, the company spent $205 million repurchasing approximately 2.3 million shares. Since the divestiture 2.5 years ago, the company has repurchased 12.5 million shares, representing 10% of the total shares outstanding at the end of Q1 2023.
New Share Repurchase Authorization: The company received a new $1 billion share repurchase authorization from the Board, replacing the existing program. This new authorization provides capacity for meaningful capital deployment in share repurchases over the next two years.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the moving pieces for 2026, including the China Diagnostics piece and software growth?
A:Prahlad Singh mentioned that the 2%-3% growth assumption for 2026 is prudent, with signs of activity normalizing, especially in China. Diagnostics ex-China is performing well, with high single-digit growth. Software has been a growth driver, and increasing customer activity in instruments is expected to contribute to demand in 2026. Maxwell Krakowiak added that the 28% operating margin baseline is tied to the 2%-3% organic growth, with potential for additional margin expansion if growth exceeds expectations.
Q:What did reagents do in the quarter, and what are the expectations moving forward?
A:Reagents were modestly lower than anticipated due to lighter summer months, but overall lab activity showed continued progress. For Q4, a similar market environment to Q3 is assumed, with some modest impact from the government shutdown.
Q:Can you elaborate on the October customer activity levels picking up?
A:Prahlad Singh stated that the increased activity is more on the pharma/biotech side, particularly in instruments, and not on the academia and government side. It is not broad-based but shows increasing pockets of activity.
Q:Should the 2%-3% organic growth with 28% operating margins translate to high single-digit EPS for 2026?
A:Yes, Maxwell Krakowiak confirmed that it would imply high single-digit EPS growth year-over-year. Interest and tax rates are expected to remain stable, with a baseline tax rate of 18%. Share buybacks will also contribute to EPS growth.
Q:Can you explain the 4Q ramp in organic growth and margins?
A:Maxwell Krakowiak explained that the 4Q ramp is driven by IDX comps, a nominal dollar increase in software, and seasonality in instrument volumes. Margins are expected to reach 30% due to higher volumes in Q4.
Q:What is the outlook for China Diagnostics and its impact on 2026?
A:China Diagnostics is down to about 6% of total sales, with a 20%-25% decline expected through Q2 2026 due to multiplex reimbursement changes. Growth is expected to return in the second half of 2026. Ex-China, the Diagnostics business continues to perform well.
Q:What type of growth outlook is embedded for the software business in 2026?
A:Mid-single-digit organic growth is expected for software in 2026, coming off a high comp year in 2025. New product launches will contribute, but their impact will take time to materialize. ARR and net retention rates remain strong.
Q:What are your M&A thoughts in light of the share repurchase program?
A:Prahlad Singh stated that the company remains disciplined in M&A deployment, with an active pipeline. However, the current focus is on share buybacks as the most attractive opportunity.
Q:Did reagents decline in Q3, and what is the margin profile for reagents going forward?
A:Reagents were down slightly year-over-year in Q3. Incremental margins remain strong, and pricing is holding despite a tighter environment. Lab activity is expected to drive margin benefits as it ramps up.
Q:Is a year-end budget flush from pharma baked into guidance?
A:Yes, a modest seasonal step-up in instrument volumes between Q3 and Q4 is assumed, but not to historical levels of budget flush.
Q:Is the 18% tax rate baseline for 2026 sustainable, and is there room for more leverage?
A:The 18% baseline is sustainable, and while there may be onetime benefits, they are not included in the guidance. The tax team has significantly improved the baseline from 20% in previous years.
Q:What is the outlook for China Diagnostics in 2026?
A:China Diagnostics is expected to stabilize at low single-digit growth in the second half of 2026 after a 20%-25% decline through Q2. Ex-China, the Diagnostics business continues to perform well.
Q:Is the improvement in instrumentation due to China tariffs or broader customer activity?
A:The improvement is due to broader customer activity, particularly from pharma/biotech customers, and not related to China tariffs.
Q:What is the outlook for reagents growth in 2026?
A:Reagents growth is expected to align with the 2%-3% organic growth guidance, assuming a similar market environment to the current one. No significant ramp-up in market activity is factored in.
Q:How much of your manufacturing for China sales is localized?
A:All reproductive health and newborn screening products are manufactured in China for China. Over half of IDX products are localized, with the rest being unique assays shipped from Germany.
Q:What is the contribution of gel products in 2026?
A:Gel products contributed $10 million in the second half of 2025, with a slight sequential pickup in Q4. This level is expected to remain consistent in 2026.
Q:What is driving the incremental enthusiasm in pharma/biotech?
A:The activity is primarily from large and midsized biotech companies, which are traditional customers, rather than smaller biotech firms.
Q:Should we anchor towards the lower end of the 2%-4% organic growth range for the full year?
A:The midpoint of the range suggests 2%-3% organic growth for Q4, which aligns with the full-year guidance.
Q:How did U.S. academic and government perform in Q3, and what is the impact of a government shutdown?
A:U.S. academic and government were down mid-single digits in Q3. A modest impact from the government shutdown is assumed for Q4, primarily affecting reagents.
Q:Is AI a threat or opportunity for Revvity products?
A:AI is seen as an opportunity. In the short to midterm, it will drive demand for reagents and instruments. In the long term, the Signals business is well-positioned to integrate AI into drug discovery.
Q:What instruments are expected to recover first, and will you provide book-to-bill data?
A:Cellular imaging and high-content screening platforms are expected to recover first. The company does not plan to provide book-to-bill data.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the impact of AI on long-term demand for Revvity products, stating only general opportunities without quantifying potential risks or benefits. Additionally, they did not provide clarity on the exact contribution of new product launches to 2026 software growth, citing the time required for adoption.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAA rating
AI advancement
AI content
AI enzyme
AI product
AI software
AI solution
AI world
ESG
Freddie
Genomics England
Sanofi
approval
assay
capacity
collaboration
commitment
discovery
disease
divestiture year
employee
eye
family
flow generation
franchise
fruition
generation capital
image
market environment
moment
month life
plex
potential
progress partnership
science
scientist
solution market
study
type diabetes
work
RVTY Transcript
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call indicates solid financial performance, particularly with strong margins and EPS growth. The launch of the AI platform and strategic acquisitions like ACD/Labs are positive catalysts. The Q&A highlights robust customer engagement and strong SaaS growth, despite short-term organic growth challenges. The divestiture strategy is seen as a positive move, enhancing long-term margins and reducing risk exposure. Although there are some uncertainties, the overall sentiment remains positive, with potential for stock price appreciation in the short term.
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
RVTY Slides
RVTY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
